In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about the impact of residual symptoms on patients with major depressive disorder, as well as treatment modifications to address residual symptoms in these individuals. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the burden of residual symptoms in patients with major depressive disorder (MDD) Implement measurement-based care to assess residual MDD symptoms Modify treatment strategies to address residual MDD symptoms, including cognitive impairment, anhedonia, emotional blunting, and sexual dysfunction Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Vladimir Maletic, MD, MS Clinical Professor, Department of Psychiatry and Behavioral Science, University of South Carolina School of Medicine Greenville, SC Consultant/ Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Biogen/Sage, Boehringer Ingelheim, Cervel, Intra-Cellular, Janssen, Jazz, Lundbeck, Neurelis, Neumora, Noven, Otsuka, Pax Medica, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Axsome, Corium, Intracellular, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda Pre-Interview Author Caroline L. O’Brien, MS Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Takeda. Released: November 29, 2023      CME/CE credit expires: November 29, 2026

In this episode, Dr. Vladimir Maletic addresses your unanswered questions from his presentations, “From Despair to Delight: Advances in the Diagnosis and Treatment of Anhedonia” and “Ho Hum to Aha! Treating Anhedonia and Emotional Blunting.”

In this episode, Dr. Leslie Citrome addresses your unanswered questions from his presentation, There’s No Place Like Home: Addressing Agitation in Dementia.

What is the role of the 5HT2A receptor in the therapeutic actions of psychedelics? What additional mechanisms may be involved in the therapeutic benefits of classic psychedelics? Is the psychedelic trip necessary for the therapeutic benefit of psychedelics?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry.  Today, Dr. Andy Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl about the current understanding of the neurobiological mechanisms underlying the therapeutic benefits of psychedelics.  Let’s listen to Part 2 of our theme: Classic Psychedelics for the Modern Psychopharmacologist.  Subscribe to the NEI Podcast, so that you don’t miss another episode!   

In this episode, Dr. Laxman Bahroo addresses your unanswered questions from his presentation, Neurology for Psychiatrists.

In this episode, Dr. Roger McIntyre addresses your unanswered questions from his presentation, Unveiling the Therapeutic Potential: Evidence Supporting the Use of Psychedelics for PTSD, SUD, and Other Indications, at the Pre-Conference Psychedelics Workshop.

In this episode, Dr. Timothy Wilens addresses your unanswered questions from his presentation, Double Trouble: Diagnosis and Pharmacotherapy of ADHD and Juvenile Bipolar Disorder, at the Child & Adolescent Psychiatry Academy.

In this episode, Dr. Robyn Thom addresses your unanswered questions from her presentation, The Full Picture: Managing Autism Spectrum Disorder and Its Frequent Psychiatric Comorbidities, at the Child & Adolescent Psychiatry Academy.

In this episode, Dr. Jeffrey Strawn addresses your unanswered questions from his presentation, Along for the Ride: Treatment Considerations for Childhood Psychiatric Disorders With Co-Occurring Anxiety, at the Child & Adolescent Psychiatry Academy.

Stigma surrounding mental illness and its treatment can be pervasive and negatively impact the quality of life of patients suffering with mental health problems. What role do psychiatric healthcare providers play in addressing and combating mental illness stigma? How do cultural factors influence the perception of mental illness and stigma? What are the best strategies for reducing stigma related to mental illness? Dawn I. Velligan, PhD is a Professor in the Department of Psychiatry, Chief of the Division of Community Recovery, Research and Training, and the Henry B. Dielmann Chair at the University of Texas Health Science Center in San Antonio, Texas. Dr. Velligan’s internationally recognized research program focuses on the development and testing of psychosocial treatments to improve medication interest, follow-through, and outcomes for people with schizophrenia. She developed cognitive adaptation training; a treatment designed to improve functional outcomes for people with serious mental illness. Dr. Velligan is an author of numerous publications in high impact journals and has received grant funding from the National Institutes of Health, The National Alliance for Research on Schizophrenia and Depression, industry, and private foundations.